 "Laurus Labs Q2 profit up 14% at Rs 233 cr, revenue jumps to Rs 1,576 cr")
Drug firm Laurus Labs on Friday said its consolidated net profit increased 14 per cent to Rs 233 crore in the second quarter ended September 30, 2022.
The company had reported a net profit of Rs 204 crore in July-September period a year ago.
Revenue from operations rose to Rs 1,576 crore in the quarter from Rs 1,203 crore in the year-ago period, Laurus Labs said in a statement.
Laurus Labs Founder and CEO Satyanarayana Chava said the results reflect the company's efforts towards strengthening and diversifying its business.
He noted that the company has developed a novel delivery for pediatric HIV treatment and expects to file an NDA (new drug application) shortly.
"This should significantly enhance our market position. Our capital allocation priorities remain unchanged. We will continue to prioritise investments in our pipeline..," Chava stated.
On business outlook, he said, "Looking forward to the second half of 2023, we expect to deliver a strong underlying revenue growth and stable EBITDA margins of 30 per cent in FY2023.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app